Finanzen von Onkure Therapeutics Inc (OKUR)OKUROnkure Therapeutics Inc

Evaluating the bottom line, Onkure Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -55.18%, provide a clear picture of how effectively OKUR converts its operational activities into shareholder value.

In the context of the broader market, OKUR competes directly with industry leaders such as PYPD and TLSA. With a market capitalization of $102.26M, it holds a significant position in the sector. When comparing efficiency, OKUR's gross margin of N/A stands against PYPD's N/A and TLSA's N/A. Such benchmarking helps identify whether Onkure Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Onkure has faced significant financial challenges, with a net income loss of approximately $15 million in the last reported quarter and a negative EPS trend. However, the current ratio is strong at 26.75, indicating good liquidity.